Rusfertide (Mimrylo)

Rusfertide is a real, FDA-approved first-in-class peptide that mimics hepcidin, the body's own master iron-regulating hormone, to control the excess red blood cell production that drives polycythemia vera. It's a genuinely new drug class this site hasn't covered before — built to reduce a patient's reliance on therapeutic phlebotomy rather than compete with an existing mechanism — and it cleared a real, statistically decisive placebo-controlled Phase 3 trial before its 28 August 2026 approval.

A first-in-class hepcidin mimetic

Polycythemia vera (PV) is a chronic bone marrow disorder, almost always driven by a JAK2 gene mutation, that causes the body to overproduce red blood cells. The excess cells thicken the blood and raise the risk of stroke, heart attack and clotting events, so the core of PV management has long been keeping hematocrit (the fraction of blood that's red cells) below 45% — a threshold established by the randomized CYTO-PV trial, which found meaningfully fewer cardiovascular deaths and major thrombotic events at that target. The traditional way to hit that target is therapeutic phlebotomy — repeatedly removing blood, the same principle as a blood donation — alongside cytoreductive drugs such as hydroxyurea, interferon or the JAK inhibitor ruxolitinib for higher-risk patients. Rusfertide works through an entirely different lever: hepcidin, the liver-produced hormone that normally acts as the body's master iron regulator, restricting how much iron is available to make new red blood cells by degrading ferroportin, the protein that exports iron out of cells and into circulation. Many PV patients have inappropriately low hepcidin relative to how hard their marrow is driving red cell production; rusfertide, a synthetic 24-amino-acid peptide developed by Protagonist Therapeutics using its peptide-display discovery platform, restores that missing brake by mimicking hepcidin directly, restricting iron supply to erythropoiesis and lowering hematocrit without the direct marrow suppression a cytoreductive drug produces.

REVIVE: the Phase 2 proof of concept

Rusfertide's first controlled human evidence came from REVIVE (Kremyanskaya M, Kuykendall AT, Pemmaraju N, et al., "Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera," N Engl J Med 2024;390(8):723-735, PMID 38381675, DOI: 10.1056/NEJMoa2308809), an international, two-part Phase 2 trial. Part 1 was a 28-week open-label dose-finding period in which most enrolled patients achieved hematocrit control without phlebotomy on rusfertide added to their existing therapy. Part 2 then randomized patients 1:1 to continue rusfertide or switch to placebo for a further 12 weeks, blinded — a randomized-withdrawal design built specifically to isolate the drug's own effect from a placebo response or regression to the mean. During that withdrawal period, a response (maintained hematocrit control without a phlebotomy) was seen in roughly 60% of patients who stayed on rusfertide, versus about 17% of those switched to placebo — a real, clinically meaningful separation on a design built to rule out the most obvious confound in a chronic-disease trial like this one.

VERIFY: the Phase 3 trial that won approval

The pivotal trial behind Mimrylo's approval was VERIFY (NCT05210790), a global, multicenter, double-blind, placebo-controlled Phase 3 trial that randomized 293 adults with PV whose disease remained inadequately controlled by standard of care — meaning they still needed therapeutic phlebotomy despite ongoing cytoreductive therapy or phlebotomy alone — to add rusfertide or placebo to that existing standard of care. On the primary endpoint, a composite response (hematocrit control without phlebotomy eligibility) assessed during weeks 20-32, 76.9% of rusfertide-treated patients responded versus 32.9% on placebo, and the trial met all four of its prespecified key secondary endpoints. Patients on rusfertide needed a mean of 0.5 phlebotomies during weeks 0-32, versus 1.8 on placebo. Longer-term data presented afterward showed durability out to a year: 61.9% of patients continuously treated with rusfertide maintained phlebotomy-free status from baseline through week 52. Rusfertide was generally well tolerated through the full 52 weeks, with injection-site reactions and anemia the most frequently reported adverse events.

A fast-tracked approval, and the Takeda deal behind it

Rusfertide picked up FDA Orphan Drug and Fast Track designations in 2020, then Breakthrough Therapy Designation in 2021 on the strength of its Phase 2 data — all before a single Phase 3 patient had completed a full year on the drug. On 31 January 2024, Protagonist Therapeutics, which discovered and had been developing rusfertide alone, signed a worldwide license and collaboration agreement with Takeda: Takeda paid $300 million upfront for exclusive rights outside the US and a 50:50 US co-development and co-commercialization arrangement, with Protagonist eligible for up to $330 million more in milestones. In April 2026, Protagonist exercised a contractual option to instead take a larger cash payout — up to $400 million in opt-out payments plus a $75 million FDA-approval milestone (up to $475 million total) — along with worldwide royalties, giving up its 50:50 US profit share. Takeda and Protagonist filed the New Drug Application in January 2026; the FDA accepted it and granted Priority Review the following March, and approved Mimrylo (rusfertide) on 28 August 2026 for the treatment of erythrocytosis in adults with polycythemia vera — the first FDA approval for a hepcidin-mimetic drug in any indication.

Current status

Mimrylo carries no boxed warning. Its label warns of new or worsening thrombocytosis (an elevated platelet count, which needs monitoring), injection-site reactions, and embryo-fetal toxicity (with corresponding contraception guidance); the most common adverse reactions in the VERIFY trial, each occurring in more than 15% of patients, were injection-site reactions (56%) and anemia (16%). It's dosed as a once-weekly, self-administered subcutaneous injection starting at 19mg, titrated within a 9.5-108mg range to hematocrit response, and is positioned as an add-on to existing standard-of-care PV management — phlebotomy, hydroxyurea, interferon or ruxolitinib — rather than a replacement for all of it. As the first approved drug in its mechanism class, rusfertide gives PV patients who remain phlebotomy-dependent despite standard therapy a genuinely new lever to pull, rather than another entrant competing on an already-crowded mechanism.